By investigating the survival advantage conferred by the addition of originator trastuzumab to standard chemotherapy regimens and by comparing the most widely used trastuzumab regimens, we will further inform the treatment of patients with HER2+ early breast cancer. The gene discussed is ERBB2; the disease is breast cancer.